New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new insights into the structure of a human virus that causes blood cancer. In their ...
Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...
New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new insights into the structure of ...
In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain. The Dutch biotech has secured an exclusive option to evaluate ...
Biologists have engineered adeno-associated viruses that are better at capsid filling, potentially resulting in higher productivity.
Once perceived as mere pathogens, adenoviruses have transformed remarkably, becoming indispensable allies in the fight against genetic disorders. In an era where medical innovation is paramount, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results